Summary
Thermo Fisher Scientific Inc. (TMO) reported its 2009 fiscal year results in this 10-K filing on February 25, 2010. The company, a leader in serving science, operates through two primary segments: Analytical Technologies and Laboratory Products and Services. Despite a challenging global economic environment, TMO generated revenues of $10.11 billion. The company strategically navigated the economic downturn through productivity improvements, cost management, and targeted acquisitions, such as Biolab and B.R.A.H.M.S. AG, to expand its portfolio and geographic reach. Financially, the company demonstrated resilience with operating income of $1.05 billion and robust cash flow from operations totaling $1.66 billion. TMO maintained a strong liquidity position with $1.57 billion in cash and short-term investments. The company also continued to invest in research and development, spending $246.1 million in 2009 to drive innovation and maintain its competitive edge in rapidly evolving scientific markets. While facing headwinds from decreased demand in certain sectors, TMO's diversified business model and strategic focus on growth platforms provided a stable foundation.
Financial Highlights
55 data points| Revenue | $9.91B |
| Cost of Revenue | $5.16B |
| Gross Profit | $4.76B |
| SG&A Expenses | $2.59B |
| Operating Expenses | $8.91B |
| Operating Income | $1.00B |
| Interest Expense | $118.00M |
| Net Income | $850.30M |
| EPS (Basic) | $2.06 |
| EPS (Diluted) | $2.01 |
| Shares Outstanding (Basic) | 412.40M |
| Shares Outstanding (Diluted) | 422.80M |
Key Highlights
- 1Total revenues for fiscal year 2009 were $10.11 billion, a slight decrease from $10.50 billion in 2008, impacted by global economic conditions.
- 2Operating income was $1.05 billion in 2009, down from $1.23 billion in 2008, reflecting efforts to manage costs amidst lower demand.
- 3The company successfully executed strategic acquisitions in 2009, including Biolab and B.R.A.H.M.S. AG, to broaden its product offerings and market presence.
- 4Cash flow from operations remained strong, totaling $1.66 billion in 2009, indicating efficient working capital management.
- 5Thermo Fisher Scientific invested $246.1 million in Research & Development in 2009, underscoring its commitment to innovation and technological advancement.
- 6The company maintained a healthy liquidity position with $1.57 billion in cash and short-term investments as of December 31, 2009.
- 7Revenues from the Analytical Technologies segment decreased by 7% year-over-year, while Laboratory Products and Services saw a marginal decrease of 0% in 2009, demonstrating relative stability in the latter segment.